We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
Read MoreHide Full Article
Shares of BridgeBio Pharma, Inc. (BBIO - Free Report) were up 14% on Thursday May 12, after management announced that BBIO has inked an exclusive licensing deal with Bristol Myers (BMY - Free Report) to develop and commercialize its SHP-2 inhibitor BBP-398, targeting oncology indications.
Per the terms of the agreement, BridgeBio will receive $90 million as an upfront payment from Bristol Myers. BBIO is also eligible to receive up to $815 million of potential milestones as well as tiered royalties in low-to-mid teens.
In addition, BridgeBio will have an option to receive higher royalties on U.S. sales of the drug, provided it funds a portion of development costs upon initiation of registrational studies.
BridgeBio is currently evaluating BBP-398 in three phase I monotherapy and combination studies on solid tumors. While BBIO will continue to lead the ongoing phase I studies on BBP-398, Bristol Myers will lead as well as fund all the future clinical studies evaluating the candidate.
Shares of BridgeBio have plunged 64.4% in the year so far compared with the industry’s 31.9% decline.
Image Source: Zacks Investment Research
This licensing agreement between BridgeBio and Bristol Myers is an extension of the non-exclusive clinical collaboration contract signed by the two companies last July. Both companies had reached an agreement to study BBP398 in combination with Opdivo, Bristol Myers’ blockbuster PD-L1 inhibitor, for treating advanced solid tumors carrying KRAS mutations.
Earlier this January, BridgeBio also entered into a non-exclusive clinical collaboration with Amgen (AMGN - Free Report) to evaluate the combination of BBP-398 with Amgen’s KRAS G12C inhibitor Lumakras in patients with KRAS G12C-mutated advanced solid tumors. Per the agreement terms, BBIO will be responsible for sponsoring the study, while Amgen will be in charge of the worldwide supply of Lumakras.
Currently, BBIO has more than 30 programs in its pipeline and multiple ongoing clinical studies. Most of these pipeline programs are a result of its tie-ups with academic institutions and industry partners.
More than two-third of BridgeBio’s pipeline programs are in collaboration with the leading academic institutions like Columbia University, University of Texas and Standford University. The milestone fees received from Bristol Myers will help BBIO fund these programs, thereby enabling it to develop its pipeline.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have risen 14.2% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
Shares of BridgeBio Pharma, Inc. (BBIO - Free Report) were up 14% on Thursday May 12, after management announced that BBIO has inked an exclusive licensing deal with Bristol Myers (BMY - Free Report) to develop and commercialize its SHP-2 inhibitor BBP-398, targeting oncology indications.
Per the terms of the agreement, BridgeBio will receive $90 million as an upfront payment from Bristol Myers. BBIO is also eligible to receive up to $815 million of potential milestones as well as tiered royalties in low-to-mid teens.
In addition, BridgeBio will have an option to receive higher royalties on U.S. sales of the drug, provided it funds a portion of development costs upon initiation of registrational studies.
BridgeBio is currently evaluating BBP-398 in three phase I monotherapy and combination studies on solid tumors. While BBIO will continue to lead the ongoing phase I studies on BBP-398, Bristol Myers will lead as well as fund all the future clinical studies evaluating the candidate.
Shares of BridgeBio have plunged 64.4% in the year so far compared with the industry’s 31.9% decline.
Image Source: Zacks Investment Research
This licensing agreement between BridgeBio and Bristol Myers is an extension of the non-exclusive clinical collaboration contract signed by the two companies last July. Both companies had reached an agreement to study BBP398 in combination with Opdivo, Bristol Myers’ blockbuster PD-L1 inhibitor, for treating advanced solid tumors carrying KRAS mutations.
Earlier this January, BridgeBio also entered into a non-exclusive clinical collaboration with Amgen (AMGN - Free Report) to evaluate the combination of BBP-398 with Amgen’s KRAS G12C inhibitor Lumakras in patients with KRAS G12C-mutated advanced solid tumors. Per the agreement terms, BBIO will be responsible for sponsoring the study, while Amgen will be in charge of the worldwide supply of Lumakras.
Currently, BBIO has more than 30 programs in its pipeline and multiple ongoing clinical studies. Most of these pipeline programs are a result of its tie-ups with academic institutions and industry partners.
More than two-third of BridgeBio’s pipeline programs are in collaboration with the leading academic institutions like Columbia University, University of Texas and Standford University. The milestone fees received from Bristol Myers will help BBIO fund these programs, thereby enabling it to develop its pipeline.
BridgeBio Pharma, Inc. Price
BridgeBio Pharma, Inc. price | BridgeBio Pharma, Inc. Quote
Zacks Rank & Stock to Consider
BridgeBio currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Alkermes (ALKS - Free Report) , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have risen 14.2% year to date.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.